1. Avelumab plus carboplatin is safe and effective in treating metastatic castration-resistant prostate cancer, according to an open-label Phase Ib study.
2. The combination therapy showed promising results in terms of overall response rate and progression-free survival.
3. Adverse events were manageable and consistent with the known safety profiles of both drugs.
由于本文仅提供了文章的元数据,无法对其内容进行详细分析和批判性评估。建议提供完整的文章内容以便进行更深入的分析。